NCT05068921 - A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 9, 2021

Primary Completion Date

May 31, 2023

Study Completion Date

July 31, 2023

Conditions

Advanced Cervical Cancer

Interventions

DRUG

TQB2858 injection

TQB2858 is an anti-programmed death ligand 1（PD-L1）/transforming growth factor-β （TGF-β） bi-functional fusion protein.

Trial Locations (17)

130000

RECRUITING

Affiliated Hospital of Changchun University of Chinese Medicine, Changchun

161099

RECRUITING

The Third Affiliated Hospital of Qiqihar Medical College, Qiqihar

250012

RECRUITING

Qilu Hospital of Shandong University, Jinan

RECRUITING

Qilu Hospital of Shandong University, Jinan

264099

RECRUITING

Yantai Yuhuangding Hospital, Yantai

266001

RECRUITING

Affiliated Hospital of Qingdao University, Qingdao

266042

RECRUITING

Qingdao Central Hospital, Qingdao

271099

RECRUITING

The Second Affiliated Hospital of Shandong First Medical University, Taian

276000

RECRUITING

Linyi Tumor Hospital, Linyi

300060

RECRUITING

Tianjin Cancer Hospital, Tianjin

410013

RECRUITING

Hunan Cancer Hospita, Changsha

530021

RECRUITING

Affiliated Tumor Hospital of Guangxi Medical University, Nanning

610042

RECRUITING

Sichuan Cancer Hospita, Chengdu

646000

RECRUITING

Affiliated Hospital of Southwest Medical University, Luzhou

RECRUITING

Affiliated Hospital of Southwest Medical University, Luzhou

710061

RECRUITING

The First Affiliated Hospital of Xi 'an Jiaotong University, Xian

046000

RECRUITING

Affiliated Peace Hospital of Changzhi Medical College, Changzhi